Dr. Reddy’s New Launch in US

Dr. Reddy’s New Launch in USDr. Reddy's recent launch in US has witnessed several after-effects in the country's market and the value of its shares.

The base of the news is the launch of Atorvastatin Calcium Tablets i. e. a bioequivalent of Lipitor in the US in all sizes i. e. 10mg, 20mg, 40mg and 80mg by Dr. Reddy's Laboratories.

Reports from Business Standard are confirming that the launch has prompted the company's shares to reach a new position by touching an intraday high of Rs 1,697.95 and an intraday low of Rs 1,680. At 09:35 hrs, the company's shares in the market stood at Rs. 1,690.90, which is up by Rs. 18.90, or 1.13%.

The company was seen trading in the market with volumes of 6,996 shares. As far as previous trading session is concerned, the shares were down by approx 1.85% or by Rs. 31.55 at Rs 1,672. Wednesday's figures also confirm that the ADR closed down by 2.04% at USD 30.75.

People are awaiting the announcements from the company regarding its Q1FY13 numbers, which it has plans to announce today.

Dr. Reddy's Laboratories is an integrated global pharmaceutical company. It has won an approval over its Atorvastatin Calcium tablets from the United States Food & Drug Administration (USFDA).